drugset / Trial / NCT06213324
Neural Circuit Effects of Ketamine in Depression
Phase 4
Recruiting
120 enrolled
Icahn School of Medicine at Mount Sinai
National Institute of Mental Health (NIMH) · collab
RandomizedParallel-groupQuadruple-blindBasic science
Summary
This project is designed to examine the role of the subgenual anterior cingulate cortex (sgACC) in anhedonia and anxiety in humans with depression, as well as the acute and sustained effects of ketamine on agACC activation and depression symptoms.
Timeline
- Start
- 2024-01-31
- Primary completion
- 2028-03-30
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | 0.5 mg/kg | Intravenous |